FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2732225635> ?p ?o ?g. }

• W2732225635 endingPage "3122" @default.
• W2732225635 startingPage "3113" @default.
• W2732225635 abstract "Purpose To describe benefits and toxicities of adjuvant endocrine therapies in women younger than 35 years with breast cancer (n = 582) enrolled in the Suppression of Ovarian Function Trial (SOFT) and Tamoxifen and Exemestane Trial (TEXT). Methods In SOFT, women still premenopausal after surgery with or without chemotherapy were randomly assigned to tamoxifen alone, tamoxifen plus ovarian function suppression (OFS), or exemestane plus OFS. In TEXT, all received OFS with or without concomitant chemotherapy and were randomly assigned to exemestane plus OFS or tamoxifen plus OFS. We summarize treatment efficacy, quality of life, and adherence of the cohort of women younger than 35 years in SOFT and TEXT, alongside data from the cohort of older premenopausal women. Results For 240 human epidermal growth factor receptor 2–negative patients younger than 35 years enrolled in SOFT after receiving chemotherapy, the 5-year breast cancer–free interval (BCFI) was 67.1% (95% CI, 54.6% to 76.9%) with tamoxifen alone, 75.9% with tamoxifen plus OFS (95% CI, 64.0% to 84.4%), and 83.2% with exemestane plus OFS (95% CI, 72.7% to 90.0%). For 145 human epidermal growth factor receptor 2–negative patients younger than 35 years in TEXT, 5-year BCFI was 79.2% (95% CI, 66.2% to 87.7%) with tamoxifen plus OFS and 81.6% (95% CI, 69.8% to 89.2%) with exemestane plus OFS. The most prominent quality of life symptom for patients younger than 35 years receiving OFS was vasomotor symptoms, with the greatest worsening from baseline at 6 months (on the order of 30 to 40 points), but loss of sexual interest and difficulties in becoming aroused were also clinically meaningful (≥ 8-point change). The level of symptom burden was similar in older premenopausal women. A total of 19.8% of women younger than 35 years stopped all protocol-assigned endocrine therapy early. Conclusion In women younger than 35 years with hormone receptor–positive breast cancer, adjuvant OFS combined with tamoxifen or exemestane produces large improvements in BCFI compared with tamoxifen alone. Menopausal symptoms are significant but are not worse than those seen in older premenopausal women." @default.
• W2732225635 created "2017-07-14" @default.
• W2732225635 creator A5003588327 @default.
• W2732225635 creator A5005951305 @default.
• W2732225635 creator A5008089396 @default.
• W2732225635 creator A5011090752 @default.
• W2732225635 creator A5017334876 @default.
• W2732225635 creator A5018701322 @default.
• W2732225635 creator A5022310549 @default.
• W2732225635 creator A5025238669 @default.
• W2732225635 creator A5026301798 @default.
• W2732225635 creator A5027201197 @default.
• W2732225635 creator A5034035919 @default.
• W2732225635 creator A5036344172 @default.
• W2732225635 creator A5040290360 @default.
• W2732225635 creator A5046031005 @default.
• W2732225635 creator A5048276210 @default.
• W2732225635 creator A5049115066 @default.
• W2732225635 creator A5052159944 @default.
• W2732225635 creator A5053376791 @default.
• W2732225635 creator A5055301443 @default.
• W2732225635 creator A5056283216 @default.
• W2732225635 creator A5064806381 @default.
• W2732225635 creator A5070351685 @default.
• W2732225635 creator A5073000306 @default.
• W2732225635 creator A5074162103 @default.
• W2732225635 creator A5078263161 @default.
• W2732225635 creator A5080353398 @default.
• W2732225635 creator A5082587759 @default.
• W2732225635 date "2017-09-20" @default.
• W2732225635 modified "2023-10-14" @default.
• W2732225635 title "Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials" @default.
• W2732225635 cites W1831196039 @default.
• W2732225635 cites W1890169097 @default.
• W2732225635 cites W1996337195 @default.
• W2732225635 cites W2038057961 @default.
• W2732225635 cites W2057271347 @default.
• W2732225635 cites W2079005652 @default.
• W2732225635 cites W2091640600 @default.
• W2732225635 cites W2098095853 @default.
• W2732225635 cites W2102392885 @default.
• W2732225635 cites W2118696602 @default.
• W2732225635 cites W2134839096 @default.
• W2732225635 cites W2135415635 @default.
• W2732225635 cites W2141366801 @default.
• W2732225635 cites W2155609785 @default.
• W2732225635 cites W2162149241 @default.
• W2732225635 cites W2169649287 @default.
• W2732225635 cites W2279220517 @default.
• W2732225635 cites W2333641069 @default.
• W2732225635 cites W2339149872 @default.
• W2732225635 cites W2419411016 @default.
• W2732225635 cites W2505695170 @default.
• W2732225635 cites W2513446666 @default.
• W2732225635 doi "https://doi.org/10.1200/jco.2016.72.0946" @default.
• W2732225635 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5597253" @default.
• W2732225635 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28654365" @default.
• W2732225635 hasPublicationYear "2017" @default.
• W2732225635 type Work @default.
• W2732225635 sameAs 2732225635 @default.
• W2732225635 citedByCount "89" @default.
• W2732225635 countsByYear W27322256352017 @default.
• W2732225635 countsByYear W27322256352018 @default.
• W2732225635 countsByYear W27322256352019 @default.
• W2732225635 countsByYear W27322256352020 @default.
• W2732225635 countsByYear W27322256352021 @default.
• W2732225635 countsByYear W27322256352022 @default.
• W2732225635 countsByYear W27322256352023 @default.
• W2732225635 crossrefType "journal-article" @default.
• W2732225635 hasAuthorship W2732225635A5003588327 @default.
• W2732225635 hasAuthorship W2732225635A5005951305 @default.
• W2732225635 hasAuthorship W2732225635A5008089396 @default.
• W2732225635 hasAuthorship W2732225635A5011090752 @default.
• W2732225635 hasAuthorship W2732225635A5017334876 @default.
• W2732225635 hasAuthorship W2732225635A5018701322 @default.
• W2732225635 hasAuthorship W2732225635A5022310549 @default.
• W2732225635 hasAuthorship W2732225635A5025238669 @default.
• W2732225635 hasAuthorship W2732225635A5026301798 @default.
• W2732225635 hasAuthorship W2732225635A5027201197 @default.
• W2732225635 hasAuthorship W2732225635A5034035919 @default.
• W2732225635 hasAuthorship W2732225635A5036344172 @default.
• W2732225635 hasAuthorship W2732225635A5040290360 @default.
• W2732225635 hasAuthorship W2732225635A5046031005 @default.
• W2732225635 hasAuthorship W2732225635A5048276210 @default.
• W2732225635 hasAuthorship W2732225635A5049115066 @default.
• W2732225635 hasAuthorship W2732225635A5052159944 @default.
• W2732225635 hasAuthorship W2732225635A5053376791 @default.
• W2732225635 hasAuthorship W2732225635A5055301443 @default.
• W2732225635 hasAuthorship W2732225635A5056283216 @default.
• W2732225635 hasAuthorship W2732225635A5064806381 @default.
• W2732225635 hasAuthorship W2732225635A5070351685 @default.
• W2732225635 hasAuthorship W2732225635A5073000306 @default.
• W2732225635 hasAuthorship W2732225635A5074162103 @default.
• W2732225635 hasAuthorship W2732225635A5078263161 @default.
• W2732225635 hasAuthorship W2732225635A5080353398 @default.
• W2732225635 hasAuthorship W2732225635A5082587759 @default.
• W2732225635 hasBestOaLocation W27322256352 @default.
• W2732225635 hasConcept C121608353 @default.

• next